{"id":"regeneron-casirivimab-imdevimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL4650248","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Casirivimab and imdevimab are recombinant human monoclonal antibodies that target non-overlapping epitopes on the spike protein of SARS-CoV-2. By binding to the spike protein, they prevent the virus from attaching to and entering human cells, thereby neutralizing viral infectivity. The combination approach reduces the risk of viral escape mutants.","oneSentence":"This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:00.650Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)"}]},"trialDetails":[{"nctId":"NCT04790786","phase":"PHASE4","title":"UPMC OPTIMISE-C19 Trial, a COVID-19 Study","status":"TERMINATED","sponsor":"Erin McCreary","startDate":"2021-03-10","conditions":"Covid19","enrollment":4571},{"nctId":"NCT05157997","phase":"PHASE1","title":"Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2022-01","conditions":"COVID-19, Organ Transplant","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"CHEST X-RAY ABNORMAL"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRY MOUTH"},{"count":1,"reaction":"DYSPNOEA"},{"count":1,"reaction":"HAEMOPTYSIS"},{"count":1,"reaction":"LUNG OPACITY"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Regeneron Casirivimab + Imdevimab","genericName":"Regeneron Casirivimab + Imdevimab","companyName":"Erin McCreary","companyId":"erin-mccreary","modality":"Biologic","firstApprovalDate":"","aiSummary":"This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells. Used for COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}